The upgrade of digital intelligence boosts the industrial application of cell factories—Interview with Dr. Xie Haitao, Chairman of Xiankangda Group
2022-04-11
Sino-US Cell : The Pioneer of Stem Cell Automation —Interview with Dr. Li Tao
Zhongxu Bio : Artificial Intelligence Boosts the Intelligent and Healthy Development of the Cell Industry —Interview with Zhuo Jiahui, Chairman of Shenzhen Zhongxu Medical Group
Xiankangda Biology : The upgrade of digital intelligence promotes the industrial application of cell factories —Interview with Dr. Xie Haitao, Chairman of Xiankangda Group
Red Coral Pharmaceutical : The intelligent transformation of the biopharmaceutical industry is the general trend —Interview with Wang Zhongyu, Chairman of Red Coral Pharmaceutical Group
CUHK 365: Artificial Intelligence Empowers Biomedicine to Lead Scientific Innovation Momentum —Interview with Xiao Weipeng, General Manager of Cross-Strait Biomedical Industry Base
Guangdong Medical University: Industry-University- Research Integration Promotes Intelligent Life Medicine —Interview with Dean Lin Lin, School of Biomedical Engineering, Guangdong Medical University
Songshan Lake Management Committee: Advanced Manufacturing in Guangdong-Hong Kong-Macao Greater Bay Area is flourishing in Songshan Lake —Interview with Yi Kangming, Management Committee of Songshan Lake National High-tech Industrial Park
The digital and intelligent upgrade path of the cell industry from point to surface
Xiankangda Group is a national high-tech enterprise. Xiankangda Group is an enterprise group established by Guangdong Xiankangda as its parent company. It was founded by Dr. Xie Haitao, a national scientific and technological innovation talent. In recent years, Xiankangda Group has closely followed the pace of scientific and technological development, innovatively used high-tech intelligent technology in the development of stem cells, and the application of digital and intelligent upgrading has achieved remarkable results.
Guangdong Xiankangda Biotechnology Co., Ltd. is a national high-tech enterprise. With cell therapy as its core industry, the company has built CAR-T cell drugs, regenerative medicine, cell preparation and storage, cell technology output, cell quality testing, medical devices, Health management and other industrial clusters, the business covers the upper, middle and lower reaches of the cell industry, establishing a closed-loop industrial chain of the entire production chain, and has a regional cell preparation center and comprehensive cell bank in Songshan Lake. In 2021, Siankangda Group and Robot 365 Company reached an in-depth cooperation in Songshan Lake, Dongguan, which means that Siankangda Group has taken a solid step in the use of high-tech intelligent technology in biological scientific research. In this special topic, Dr. Xie Haitao, chairman of Xiankangda Group, a national scientific and technological innovation talent , shared in detail the company 's thoughts on the application of high-tech intelligent technology in the field of biotechnology and its prospects for the future .
Dr. Xie Haitao, Chairman of Xiankangda Group
Xie Haitao: Founded in 2015, Xiankangda Group is one of the well-known stem cell therapy R&D companies in China, with world-leading cell therapy technology. The company has built an advanced biotechnology research and development platform, developed world-leading treatment technologies, obtained various international certifications, and won numerous awards. At present, Xiankangda Group has a mature expert technical team in stem cell therapy, and has hundreds of core patented technology. In 2021, Xiankangda Group was approved to build the "Songshan Lake (Xiankangda) Regional Cell Preparation Center and Comprehensive Cell Bank". It marks that Xiankangda Group has flourished in Songshan Lake, Dongguan.
Reporter: What is stem cell therapy? Will it bring us any convenience?
Xie Haitao : Stem cells are a type of cells with self-renewal and multiple differentiation potentials, which have the potential to regenerate various tissues and organs and the human body. They are called "universal cells" in the medical community. Stem cells are actually a type of cells that are not fully mature and fully differentiated, which can replicate and continuously update themselves.
It is precisely because of these special advantages of stem cells that it can differentiate into any cell, and even into any tissue and organ. Therefore, it is also called "universal cell". Because of the particularity of stem cells, it can provide a safe and efficient medical solution for many clinical cases such as anti-aging, treatment of diabetes, and treatment of liver cirrhosis . Diseases, including spinal cord injury, multiple sclerosis, stroke, amyotrophic lateral sclerosis, Alzheimer's disease, osteoarthritis, necrosis of the femoral head, disc degeneration, myocardial infarction, liver cirrhosis, Crohn's disease, interstitial lung disease, Systemic lupus erythematosus, etc.
Scenario of the Cell R&D Laboratory of Xiankangda Group
Xie Haitao : The cell industry has a very good development prospect. As an important pillar of life science, the cell industry will have a broader prospect. Including the development of some cell products, the research and development of some new radical technologies for tumors, and the industrialization of cell products themselves are all very good development directions.
At present, the country has launched a key project of "Stem Cell Research and Organ Repair". The overall goal of the project is to focus on the key scientific issues of stem cell development and organ repair, to carry out stem cell fate regulation, organ formation and aging mechanism, organ function remodeling and manufacturing, gene Research on basic theories and key technologies in editing and regulation methods, human disease stem cell models, etc., and carry out frontier explorations such as organ regeneration regulation drugs, bioartificial organs, disease organoid models, etc., to provide important tissue and organ repair and replacement and diagnosis and treatment of major diseases. Innovation theory and technology. It is foreseeable that stem cell therapy must be one of the key plans of national development in the future.
Robot 365 Fully Automatic Cell Preparation Workstation
Reporter: What do you think is the future trend of the combination of cell industry and automation?
Xie Haitao: As an important pillar in the field of life sciences, cell
Xiankangda Group and Robot 365 reached a strategic cooperation
Reporter: What insights did you have in the process of cooperating with Robot 365?
Xie Haitao: I think the positioning of Robot 365 is very in line with the development trend of the industry, and can solve the pain points such as the standardization of the quality of our cell products. Moreover, the application of the stem cell intelligent laboratory can reduce manual errors and make the cell industry develop in a healthier direction. The cooperation process between us is very smooth. The team of Robot 365 is a group of very young and energetic scientists. Their product development efficiency is very high and they can meet the needs of our market development. I am watching the growth of Robot 365 company step by step. We hope that under the leadership of President Liu, Robot 365 can create greater value in laboratory solutions.
Reporter: What new cooperation will Xiankangda Group reach with Robot 365 next?
Xie Haitao : At present, Xiankangda Group has reached an in-depth strategic partnership with Robot 365. We will not only use Robot 365 's laboratory robots, but also continue to apply stem cell intelligent laboratory solutions, and will participate in the development of Robot 365 in the future. In the process, I hope to contribute my own strength.
